Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-22-Speech-2-038"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20021022.1.2-038"2
lpv:hasSubsequent	lp_eu:2002-10-22-Speech-2-0392
lpv:speaker	lp:Giuseppe Nistico'2
lpv:spokenAs	substitute; Committee on Industry, External Trade, Research and Energy (2002-01-17--2004-07-19)3 member; EPP-ED (1999-07-20--2004-07-19)3 unknown; Forza Italia (1999-07-20--2004-07-19)3 member; Delegation to the EU-Bulgaria Joint Parliamentary Committee (2002-10-21--2004-07-19)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3
lpv:translated text	"Mr President, Commissioner, I will focus once again on a number of what I feel to be key points. The Commission’s proposal to allow a data protection period of ten years must, in my opinion, remain a solid, immovable pillar. This position is well-balanced and will provide European industry with new incentives and impetus to continue to invest new resources in the development of more effective, safer medicinal products and make them competitive at international level at last. I feel it is important to have a sufficiently long period of data protection for well-known medicinal products too, wherever there are new therapeutic indications. As I said before, I do not support the line taken regarding the membership of the management board, which I believe should be made up solely of institutional representatives. I therefore call upon you, Commissioner, and the Council to come up with a balanced model for a management board which can work calmly, free from dispute or conflict. I am amazed, reading Amendments Nos 153 and 154, for example, to see that the directive still mentions ‘traditional herbal medicinal products’. I am the rapporteur of another report on traditional herbal medicinal products, and so I do not support Amendments Nos 153 and 154. However, Mr President, I am in favour of removing the requirement to re-license products every five years. This is an excessively bureaucratic burden. I hope that we will, at last, have a system of active pharmacovigilance operating throughout the territory which will allow us to introduce continuous monitoring carried out by highly qualified experts – Europe is teeming with clinical pharmacologists – to ensure that any toxic side effects are made known as soon as they occur."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph